GlassScriptPhysician profile
Jose Alfredo Morfin
NPI 1376528877
$1,032,547.19
in general payments reported to CMS, 2019-2025
15 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $98K · 2021: $229K · 2022: $227K · 2023: $177K · 2024: $99K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Travel and Lodging: $42K · Consulting Fee: $19K · Food and Beverage: $7,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,725.00 |
| Travel and Lodging | $41,926.02 |
| Consulting Fee | $19,075.56 |
| Food and Beverage | $7,521.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $433,706.06 | 2019-2024 | Lokelma, Farxiga |
| Nxstage Medical, INC. | $218,249.03 | 2019-2025 | Nxstage System One, Pureflow Sl, Liberty Select Cycler |
| Aurinia Pharma U.S., INC. | $125,596.82 | 2021-2024 | Lupkynis |
| Amgen INC. | $91,214.92 | 2022-2025 | Tavneos |
| Ardelyx, INC. | $67,479.48 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $31,828.84 | 2022-2025 | |
| Glaxosmithkline, LLC. | $29,379.84 | 2022-2024 | Jesduvroq, Benlysta |
| Vifor Pharma, INC. | $17,781.47 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $10,455.00 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $2,500.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $1,845.00 | 2023 | |
| Shield Therapeutics INC | $1,700.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $750.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.39 | 2025 | |
| Outset Medical INC | $11.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Morfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.